Pediarix® General Recommendations:
- Recommended for children aged 6 weeks through 6 years.
- Cannot be used for the birth dose of hepatitis B vaccine.
- Approved for the first 3 doses of the DTaP series.
- Approved for the first 3 doses of the inactivated polio vaccine (IPV) series.
- Not approved for the fourth or fifth doses of the DTaP series.
- Not approved for the booster dose of IPV at 4-6 years of age.
- Approved for use through 6 years of age for the primary schedule. If a child is behind schedule, they can receive Pediarix:  
  - for doses 1, 2, and 3 of the series, and  
  - the child is younger than 7 years old
- Pediarix may be used interchangeably with other pertussis containing vaccines if necessary.
- Three doses of Pediarix can be given to infants who received a birth dose of hepatitis B vaccine (including infants whose mothers are HBsAg positive or whose HBsAg status is unknown).
- A total of 4 doses of hepatitis B vaccine will result from use of Pediarix after the birth dose, which is considered acceptable by the ACIP.
- If a dose of Pediarix is inadvertently administered as the fourth or fifth dose of the DTaP or IPV series, it does not need to be repeated.
- Clinical studies have shown that the immune response to Pediarix is comparable to that of the separate vaccines.

Storage and Handling:
- Store Pediarix® in the refrigerator between 35°F and 46°F (aim for 40°F).
- Do not allow vaccines to freeze – do not use if frozen.

### Pediarix® Vaccine Factsheet

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Dose</th>
<th>Recommended Age</th>
<th>Schedule (3-dose primary series)</th>
<th>Minimum Age</th>
<th>Intervals</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pediarix® (GlaxoSmithKline)</td>
<td>0.5 mL IM</td>
<td>6 weeks – 6 years</td>
<td>2 months</td>
<td>6 weeks</td>
<td>Dose 1 to dose 2: 4 – 8 weeks</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>4 months</td>
<td>10 weeks</td>
<td>Dose 2 to dose 3: 8 weeks</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>6 months</td>
<td>6 months</td>
<td>At least 16 weeks after the 1st dose and not before 6 months of age.</td>
</tr>
</tbody>
</table>

### Adverse Reactions
- Expected to be the same as for those of the individual component vaccines.
- Associated with higher rates of fever, compared to separately administered component vaccines (DTaP, Hepatitis B, and IPV).

### Precautions
- Hypersensitivity to any component of the vaccine, including yeast, neomycin or polymyxin B.
- History of anaphylaxis after a previous dose of Pediarix or any of its components.
- Progressive neurologic disorder, including infantile spasms, uncontrolled epilepsy, or progressive encephalopathy.

### Contraindications
- Warnings and precautions for the individual components also apply to Pediarix.
- History of encephalopathy within 7 days of a previous dose of any pertussis-containing vaccine.
- Temperature of ≥105 °F within 48 hours of a prior dose.
- Collapse or shock-like state; persistent, inconsolable crying for 3 or more hours occurring within 48 hours of a prior dose.
- Seizures with or without fever within 3 days of a prior dose.
- Guillain-Barré syndrome within 6 weeks of a prior dose.
- Concurrent moderate or severe acute illness.

For more information on Pediarix vaccine or any other recommended vaccine, visit the Immunization Program website at [http://publichealth.lacounty.gov/ip/providers/B71.htm](http://publichealth.lacounty.gov/ip/providers/B71.htm) or call (213) 351-7800.